NEW YORK, November 17, 2015 /PRNewswire/ --
The introduction of novel immune-checkpoint inhibitors, such as Opdivo and Keytruda, will drive Non-Small Cell Lung Cancer (NSCLC) therapeutics market to 2021, says GBI Research.
Analysis from business intelligence provider GBI Research - Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - states that the global market value for NSCLC treatment will rise from $6.9 billion in 2014 to $10.9 billion by 2021, representing a Compound Annual Growth Rate (CAGR) of 8.5%.
This increase will occur across the eight major markets of the US, Canada, UK, Germany, France, Italy, Spain and Japan. For a complimentary sample of this research, please visit the GBI Research website.
Senior Analyst Joshua Libberton: "New therapies will capture a significant share of the second-line treatment space. As well as strong clinical performances commanding premium pricing, they are expected to increase the degree of segmentation in the NSCLC therapeutics market and add further complexity to the treatment algorithm.
"The majority of new drugs will target the second-line treatment of NSCLC in both squamous and non-squamous patient subsets, leading to a crowded treatment algorithm for these patient populations. Ultimately, due to their strong clinical performances, immunotherapies will have a greater uptake than other second-line market entrants, such as Custirsen and Rociletinib."
GBI Research's report also states that the NSCLC therapeutics market will also see the launches of two first-line treatments for squamous cell patients during the forecast period, namely Necitumumab, which is due to launch in early 2016, and Yervoy (ipilimumab) in 2017.
Libberton continues: "The squamous patient subset is currently very limited in terms of first-line treatment options, meaning these new drugs will be important for driving market growth and improving patient outlook.
"While generic chemotherapies will remain an integral aspect of NSCLC treatment, with platinum-based regimens being crucial in the first-line setting for all patients and docetaxel being a key therapy for second-line patients, their market share will slowly decline by 2021 as new premium, targeted therapies enter the arena."
About GBI Research
GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends.
For the full range of market-leading analysis on the pharmaceutical industry, visit GBI Research's report store.
Follow GBI Research online for the latest healthcare industry updates:
SOURCE GBI Research